c-Jun NH2-terminal kinase mediation of angiotensin II-induced proliferation of human mesangial cells
Open Access
- 1 June 2005
- journal article
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 288 (6) , F1118-F1124
- https://doi.org/10.1152/ajprenal.00220.2004
Abstract
Angiotensin II (ANG II) has been shown to activate c-Jun NH2-terminal kinase (JNK) in cultured mesangial cells, but the functional implication of this phenomenon remains to be determined, largely due to the lack of an effective approach to block JNK. Therefore, the present study was carried out to examine whether JNK is involved in ANG II-induced cell proliferation in cultured human mesangial cells (HMCs) with the use of a newly developed JNK-selective blocker, SP-600125. Within minutes, treatment with 100 nM ANG II activated all three members of MAP kinase family, including extracellular signal-regulated protein kinase (Erk) 1/2, JNK, and p38 in cultured HMCs, as assessed by immunoblotting detection of phosphorylation of MAP kinases. ANG II-dependent activation of JNK was further confirmed by detection of increased phosphorylation and transcription activity of c-Jun after the ANG II treatment. SP-600125 ranging from 5 to 10 μM almost completely abolished the activation of JNK by ANG II without affecting the activities of Erk1/2 and p38. After treatment with 100 ng ANG II, there was a steady increase in [3H]thymidine incorporation that was blocked by SP-60025 in a dose- and time-dependent manner. Similarly, SP-600125 dose dependently reduced the ANG II-induced increase in cell number. The antiproliferative effect of SP-60025 was further determined by cell-cycle analysis with flow cytometry. Twenty-four hours after ANG II treatment, 50% of the quiescent HMCs (G0/G1) progressed into the S phase, and the cell cycle progression was almost completely prevented in the presence of SP-60025. Our data suggest that JNK mediates the proliferative effect of ANG II in cultured HMCs and thus represents a novel therapeutic target for treatment of chronic renal diseases.Keywords
This publication has 35 references indexed in Scilit:
- Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125The EMBO Journal, 2004
- Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: a mechanism for activation of latent TGF-β1American Journal of Physiology-Renal Physiology, 2004
- ERK1/2 and JNKs, but not p38 kinase, are involved in reactive oxygen species‐mediated induction of osteopontin gene expression by angiotensin II and interleukin‐1β in adult rat cardiac fibroblastsJournal of Cellular Physiology, 2003
- Role of Platelet-Derived Growth Factor in Renal InjuryAnnual Review of Physiology, 1995
- Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failureKidney International, 1992
- Vasoactive agents affect growth and protein synthesis of cultured rat mesangial cellsKidney International, 1992
- Effects of Epidermal Growth Factor on Calf Renal Glomerular CellsIn VitroGrowth Factors, 1992
- Mitogenic effect of platelet-derived growth factor in human glomerular mesangial cells: modulation and/or suppression by inflammatory cytokinesClinical and Experimental Immunology, 1991
- Angiotensin II receptor-mediated proliferation of cultured human fetal mesangial cellsKidney International, 1991
- The Progression of Renal DiseaseNew England Journal of Medicine, 1988